Giovanni Peretto

Vita-Salute San Raffaele University
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Genetic variants that impair cardiac function or predispose individuals to autoimmune diseases can influence both the risk and severity of inflammatory heart diseases, including lymphocytic myocarditis and cardiac sarcoidosis. We review recent clinical and experimental studies that describe the emerging interplay between genetic susceptibility and active myocardial inflammation. We summarize the current perspective on the mechanisms of inflammatory pathways and gene‐immune interactions, and explore the emerging therapeutic approaches aimed at targeting inflammation in genetic cardiomyopathies.

Year:

2026

BACKGROUND: Ventricular electrogram duration map (VEDUM) is a new approach for the identification of the arrhythmogenic substrate critical for ventricular tachycardia (VT), and it is based on the evaluation of the prolonged bipolar electrograms. Our aim is to evaluate the prognostic role of the VEDUM area in patients with VT and ischemic cardiomyopathy. METHODS: We enrolled all patients with ischemic cardiomyopathy who underwent VT ablation in 2 different centers. After isthmus transection for VT inducible, the procedure was aimed at noninducibility of any VT plus substrate modification. For each patient, we retrospectively analyzed the amount of the VEDUM area covered during catheter ablation. The primary outcome included any recurrence of sustained VT. RESULTS: Seventy-one patients (mean age: 69.9±8.9 years; males 93%) were enrolled. The mean size of the VEDUM area was 14.6±10.3 cm 2 , and it was visualized in a low voltage area in 65 (91.6%) patients. A deceleration zone and late potentials were recorded inside the VEDUM area in 71.8% and 73.2%, respectively. During a mean follow-up of 24.4±13.9 months, the primary outcome occurred in 18 (25.4%) cases; the arrhythmia free-survival was significantly lower in patients with ablation of at least 75% of the VEDUM area (VEDUM 75%: 89.5%; log-rank P value: 0.047). The ablation of at least 50% of the VEDUM area (hazard ratio, 0.374 [0.147–0.947]; P value, 0.038) and the VT inducibility (hazard ratio, 4.087 [1.341–12.450]; P value, 0.013) represented the only predictors of VT recurrence. CONCLUSIONS: VEDUM area ablation represented a new target for catheter ablation of VT in patients with ischemic cardiomyopathy.

Year:

2025

Background Desmoplakin (DSP) cardiomyopathy, caused by variants in the gene DSP , is a unique subtype of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathies. Specific diagnostic and disease staging criteria have yet to be developed for DSP cardiomyopathy. Objective Utilizing a large cohort of DSP cardiomyopathy patients and their genotype-positive family members, this study aims to develop diagnostic and disease staging criteria for DSP cardiomyopathy. Methods Patients from the DSP -ERADOS Network with complete rhythm monitoring, electrocardiogram and cardiac magnetic resonance imaging were enrolled. Diagnostic criteria were assessed in initially-presenting patients (probands) and their genotype-positive family members. Early disease criteria (with preserved left ventricular ejection fraction, LVEF) were integrated into standard LVEF-based classifications. Diagnostic and staging criteria were assessed by time-event analyses (major ventricular arrhythmia and heart failure events). Results A total of 605 patients with complete diagnostic testing were included (mean age 40 yr, 60% female, 40% probands). The most prevalent disease features in probands were premature ventricular contractions (PVCs) >500/24hr (66%), nonsustained ventricular tachycardia (NSVT, 29%), LV late gadolinium enhancement (LGE, 53%), and reduced LVEF (44%). The presence of any one of these features was 97% sensitive for diagnosis (along with a DSP pathogenic variant) and were therefore considered as diagnostic criteria. Using these criteria, 77% of genotype-positive family members were considered clinically affected. Isolated right ventricular (RV) involvement occurred in only 0.7%. The absence of diagnostic criteria identified a low-risk group (composite event rate 0.8%/year, p 50%, HR 2.7, p=0.04; intermediate: LVEF 41-49%, HR 3.7, p=0.009; advanced: LVEF <40% HR 10.3, p<0.001). LGE was mostly subepicardial (87%). Circumferential (ring-like) LGE was more frequent in intermediate or advanced vs early disease (66% vs 48%, p<0.001). Conclusion This study identifies genotype-specific diagnostic and disease staging criteria for DSP cardiomyopathy that improve identification of risk for both heart failure and sustained ventricular arrhythmias. This work highlights how gene-specific criteria may be used to refine diagnosis and staging for cardiomyopathy subtypes – a critical step as gene-targeted treatments move toward clinical trials.

Year:

2025

Purpose: Myocarditis is frequently a sporadic disease, but may also occur in the context of genetic disorders which may increase susceptibility to cardiac inflammation. Cardiac involvement in Wolfram syndrome type 1 (WS1) has been scarcely characterized. To our knowledge, no cases of virus-negative myocarditis have been reported in the WS1 pediatric population. Methods: We report the description of a pediatric case of acute myocarditis in the context of WS1, followed by a literature review of cardiovascular involvement associated with wolframin variants, and discuss potential pathophysiological mechanisms and therapeutic options. Results: A young patient with WS1, treated with insulin and liraglutide, was admitted for acute chest pain. Cardiac magnetic resonance and endomyocardial biopsy were performed to confirm the clinical suspicion of myocarditis. While congenital heart diseases and arrhythmias have been described previously in patients with WS1, this is the first description of virus-negative myocarditis. Conclusions: Myocarditis may represent a possible manifestation of cardiovascular involvement in WS1. Cardiovascular screening may be considered in patients with WS1.

Year:

2024

Collaborators (31)

Arthur A M Wilde

University of Amsterdam

NETHERLANDS
View details

Nisha Gilotra

Assistant Professor of Medicine

Johns Hopkins University School of Medicine

UNITED STATES
View details

Firat Duru

-

SWITZERLAND
View details

Kristina Haugaa

Professor

University of Oslo

NORWAY
View details

A.s Amin

Cardiologist

Amsterdam University Medical Centers

NETHERLANDS
View details

Eric Smith

University of Michigan

UNITED STATES
View details

Julia Cadrin-Tourigny

Clinical Assistant Professor

Université de Montréal

CANADA
View details

J. Peter van Tintelen

Head Department; clinical geneticist

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Matthew Taylor

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Stefano Bianchi

Head of Unit

Fatebenefratelli Hospital

ITALY
View details

Lia Crotti

Director of the Cardiological Rehabilitation Unit, San Luca Hospital

IRCCS Istituto Auxologico Italiano

ITALY
View details

Victoria N. Parikh

Stanford University

UNITED STATES
View details

Sing-Chien Yap

Researcher

Erasmus University Rotterdam

NETHERLANDS
View details

Michela Casella

Researcher

Università Politecnica delle Marche

ITALY
View details

Adam Helms

Assistant Professor

University of Michigan

UNITED STATES
View details

Petros Syrris

University College London

UNITED KINGDOM
View details

James Ware

Professor

Imperial College London

UNITED KINGDOM
View details

Marco Merlo

University of Trieste

ITALY
View details

Marina Cerrone

Research Assistant Professor of Medicine

NYU School of Medicine

UNITED STATES
View details

Gianfranco Sinagra

University of Trieste

ITALY
View details

Barbara Bauce

Associate Professor

University of Padova

ITALY
View details

Hugh Calkins

Johns Hopkins University School of Medicine

UNITED STATES
View details

Cynthia James

Associate Professor

Johns Hopkins University

UNITED STATES
View details

cristina basso

Professore Ordinario di Anatomia Patologica

University of Padova

ITALY
View details

Kalliopi Pilichou

Associate Professor

University of Padua

ITALY
View details

Ardan M. Saguner

-

SWITZERLAND
View details

Luisa Mestroni

Professor of Medicine

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Juan Gimeno Blanes

Associate Professor

Universidad de Murcia

SPAIN
View details

Marco Schiavone

Clinical Scientist

Centro Cardiologico Monzino

ITALY
View details

Perry Elliott

University College London

UNITED KINGDOM
View details

Leslie T Cooper

Professor

Mayo Clinic Florida

UNITED STATES
View details